

Pseudoxanthoma Elasticum- Pipeline Insight, 2019

<https://marketpublishers.com/r/P81C37D9AA1EN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: P81C37D9AA1EN

Abstracts

This report can be delivered to the clients within 24 Hours

"Pseudoxanthoma Elasticum- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pseudoxanthoma Elasticum pipeline landscape is provided which includes the disease overview and Pseudoxanthoma Elasticum treatment guidelines. The assessment part of the report embraces, in depth Pseudoxanthoma Elasticum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pseudoxanthoma Elasticum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pseudoxanthoma Elasticum Understanding

Pseudoxanthoma Elasticum (PXE) also known as Groenblad-Strandberg Syndrome is a progressive disorder that is characterized by the accumulation of deposits of calcium and other minerals (mineralization) in elastic fibers. Elastic fibers are a component of connective tissue, which provides strength and flexibility to structures throughout the body. In PXE, mineralization can affect elastic fibers in the skin, eyes, and blood vessels, and less frequently in other areas such as the digestive tract. People with PXE may have yellowish bumps called papules on their necks, underarms, and other areas of skin that touch when a joint bends (flexor areas). They may also have abnormalities in the eyes, such as a change in the pigmented cells of the retina. Another eye abnormality known as angioid streaks occurs when tiny breaks form in the layer of tissue under the retina called Bruch's membrane. Bleeding and scarring of the retina may also occur, which can cause vision loss.

Pseudoxanthoma Elasticum Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pseudoxanthoma Elasticum targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pseudoxanthoma Elasticum pipeline report covers 4+ companies. Some of the key players include Inositec (INS-3001), Inozyme (INZ-701) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Pseudoxanthoma Elasticum Analytical Perspective by DelveInsight

In-depth Pseudoxanthoma Elasticum Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Pseudoxanthoma Elasticum Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Pseudoxanthoma Elasticum report provides an overview of therapeutic pipeline activity for Pseudoxanthoma Elasticum across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Pseudoxanthoma Elasticum therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Pseudoxanthoma Elasticum Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pseudoxanthoma Elasticum

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Pseudoxanthoma Elasticum to formulate effective R&D strategies

Assess challenges and opportunities that influence Pseudoxanthoma Elasticum R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Pseudoxanthoma Elasticum in licensing and out licensing strategies by identifying prospective partners with progressing projects for Pseudoxanthoma Elasticum to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in

decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. PSEUDOXANTHOMA ELASTICUM (GROENBLAD-STRANDBERG SYNDROME)

2.1. Pseudoxanthoma Elasticum Disease Overview

2.2. Pseudoxanthoma Elasticum History

2.3. Pseudoxanthoma Elasticum Symptoms

2.4. Pseudoxanthoma Elasticum Causes

2.5. Pseudoxanthoma Elasticum Pathophysiology

2.6. Pseudoxanthoma Elasticum Diagnosis

2.6.1. Diagnostic Guidelines

3. PSEUDOXANTHOMA ELASTICUM CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. PSEUDOXANTHOMA ELASTICUM - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment

4.1.1. Pseudoxanthoma Elasticum companies collaborations, Licensing, Acquisition –Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Pseudoxanthoma Elasticum Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Pseudoxanthoma Elasticum Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono / Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. PSEUDOXANTHOMA ELASTICUM PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. PSEUDOXANTHOMA ELASTICUM -PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. INS-3001- Inositec
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
 - 6.1.2. INZ-701- Inozyme
 - 6.1.2.1. Product Description
 - 6.1.2.1.1. Product Overview
 - 6.1.2.1.2. Mechanism of Action
 - 6.1.2.2. Research and Development
 - 6.1.2.2.1. Clinical Studies
 - 6.1.2.2.1.1. Detailed Study Description
 - 6.1.2.2.1.2. Study Results
 - 6.1.2.2.1.3. Clinical Trials: Tabular View
 - 6.1.2.3. Product Development Activities
 - 6.1.2.3.1. Tabulated Product Summary
 - 6.1.2.3.1.1. General Description Table

To be continued in the report.....

7. RECENT TECHNOLOGIES

8. PSEUDOXANTHOMA ELASTICUM KEY COMPANIES

- 8.1. Regeneron Pharmaceuticals
- 8.2. Novartis Ophthalmics
- 8.3. Inositec
- 8.4. Inozyme

9. PSEUDOXANTHOMA ELASTICUM KEY PRODUCTS

- 9.1. Aflibercept
- 9.2. Ranibizumab
- 9.3. INS-3001
- 9.4. INZ-701

10. DORMANT AND DISCONTINUED PRODUCTS

- 10.1. Dormant Products
 - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
 - 10.2.1. Reasons for the discontinuation

11. PSEUDOXANTHOMA ELASTICUM - UNMET NEEDS

12. PSEUDOXANTHOMA ELASTICUM - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

- 14.1. Secondary Research
- 14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Pseudoxanthoma Elasticum Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Pseudoxanthoma Elasticum Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

Figure 1. Disease Overview

Figure 2. History

Figure 3. Symptoms

Figure 4. Causes

Figure 5. Pathophysiology

Figure 6. Diagnostic Guidelines

Figure 7. Treatment Guidelines

Figure 8. Pseudoxanthoma Elasticum companies collaborations, Licensing, Acquisition –Deal Value Trends

Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis

Figure 10. Pseudoxanthoma Elasticum Acquisition Analysis

Figure 11. Assessment by Phase of Development

Figure 12. Assessment by Product Type (Mono / Combination)

Figure 13. Assessment by Stage and Product Type

Figure 14. Assessment by Route of Administration

Figure 15. Assessment by Stage and Route of Administration

Figure 16. Assessment by Molecule Type

Figure 17. Assessment by Stage and Molecule Type

Figure 18. Assessment by MOA

Figure 19. Assessment by Stage and MOA

Figure 20. Late Stage Products (Phase-III)

Figure 21. Mid Stage Products (Phase-II)

Figure 22. Early Stage Products (Phase-I)

Figure 23. Pre-clinical and Discovery Stage Products

Figure 24. Inactive Products

Figure 25. Dormant Products

Figure 26. Discontinued Products

Figure 27. Unmet Needs

KEY COMPANIES

Regeneron Pharmaceuticals

Novartis Ophthalmics

Alexion

I would like to order

Product name: Pseudoxanthoma Elasticum- Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/P81C37D9AA1EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P81C37D9AA1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970